Promising combo for inflammatory breast cancer stalls after single patient
NCT ID NCT05198843
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This early-phase trial tested a combination of two drugs—icosapent ethyl (an omega-3 fatty acid) and dasatinib (a targeted cancer drug)—in people with a rare, aggressive form of breast cancer that had spread. The goal was to find a safe dose and see if the combo could shrink tumors. However, the study was stopped early after only one person enrolled, so we have no useful information about whether the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
icosapent ethyl (an omega-3 fatty acid) and dasatinib (a targeted cancer drug)
What this could lead to
If it had worked, this combination might have pointed toward a new treatment option for a very aggressive breast cancer.
What could go wrong
The trial was terminated after enrolling only 1 person, so no meaningful conclusions can be drawn. It is too early to know if this combination is safe or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.